Abstract #3578

Metabolic response of radiotherapy in patient-derived glioblastoma xenografts using hyperpolarized magnetic resonance

Travis Salzillo¹, Vimbai Mawoneke², Joseph Weygand², Akaanksh Shetty², Joy Gumin³, Niki Zacharias², Seth Gammon², David Piwnica-Worms², Gregory Fuller⁴, Christopher Logothetis⁵, Frederick Lang³, and Pratip Bhattacharya²

¹Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, ²Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States, ³Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁴Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁵Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Glioblastoma is an aggressive cancer with a median survival of 16 months. Thus, waiting for changes in tumor volume to determine prognosis is too slow to benefit the patient. In this study, we show that in vivo measurements of tumor metabolism with hyperpolarized magnetic resonance can detect changes more rapidly and reliably than conventional anatomic MRI throughout all stages of tumor progression. These data are supported through ex vivo metabolic profiling. Interpretation of these results demonstrate the value that hyperpolarized magnetic resonance can bring to the clinic by addressing specific challenges encountered throughout the the care of glioblastoma patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here